Direct medical costs of urinary tract infections by Gram-negative bacilli resistant to beta-lactams in a tertiary care hospital in Medellín, Colombia

• Published in: Biomédica 2019-05, Vol.39 (s1), p.35-49
• Main Authors: Vargas-Alzate, Carlos Andrés, Higuita-Gutiérrez, Luis Felipe, Jiménez-Quiceno, Judy Natalia
• Format: Article
• Language: eng ; spa
• Subjects: Aged; Aged, 80 and over; Anti-Bacterial Agents - economics; beta-Lactam Resistance; beta-Lactams - pharmacology; Carbapenems - pharmacology; Cephalosporins - pharmacology; Cohort Studies; Colombia; Cross Infection - economics; Cross Infection - microbiology; Diagnostic Imaging - economics; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria - drug effects; Gram-Negative Bacteria - isolation & purification; Health Expenditures - statistics & numerical data; Hospitalization - economics; Hospitals, Urban - economics; Humans; Male; Middle Aged; Tertiary Care Centers - economics; Urinary Tract Infections - economics; Urinary Tract Infections - microbiology
• ISSN: 0120-4157
• DOI: 10.7705/biomedica.v39i1.3981

Introduction: Urinary tract infections are very frequent in the hospital environment and given the emergence of antimicrobial resistance, they have made care processes more complex and have placed additional pressure on available healthcare resources. Objective: To describe and compare excess direct medical costs of urinary tract infections due to Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas aeruginosa resistant to beta-lactams. Materials and methods: A cohort study was conducted in a third level hospital in Medellín, Colombia, from October, 2014, to September, 2015. It included patients with urinary tract infections caused by beta-lactam-susceptible bacteria, third and fourth generation cephalosporin-resistant, as well as carbapenem-resistant. Costs were analyzed from the perspective of the health system. Clinical-epidemiological information was obtained from medical records and the costs were calculated using standard tariff manuals. Excess costs were estimated with multivariate analyses. Results: We included 141 patients: 55 (39%) were sensitive to beta-lactams, 54 (38.3%) were resistant to cephalosporins and 32 (22.7%) to carbapenems. The excess total adjusted costs of patients with urinary tract infections due to cephalosporin- and carbapenem-resistant bacteria were US$ 193 (95% confidence interval (CI): US$ -347-734) and US$ 633 (95% CI: US$ -50-1316), respectively, compared to the group of patients with beta-lactam sensitive urinary tract infections. The differences were mainly found in the use of broad-spectrum antibiotics such as meropenem, colistin, and fosfomycin. Conclusion: Our results show a substantial increase in the direct medical costs of patients with urinary tract infections caused by beta-lactam-resistant Gram-negative bacilli (cephalosporins and carbapenems). This situation is of particular concern in endemic countries such as Colombia, where the high frequencies of urinary tract infections and the resistance to beta-lactam antibiotics can generate a greater economic impact on the health sector.